EUVIMEDEUVIMED entdecken
Open Access

Measuring the temporal prognostic utility of a baseline risk score

Sean M Devlin iD, Mithat Gönen, Glenn Heller

Lifetime Data Analysis · 2020-10 · 26 (4) · 856-871

DOI: 10.1007/s10985-020-09503-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lifetime Data Analysis, online erschienen am 24.07.2020. Verfasst von Sean M Devlin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. devlins@mskcc.org. Hauptthemen laut MEDLINE: Prognosis, Proportional Hazards Models. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the time-to-event setting, the concordance probability assesses the relative level of agreement between a model-based risk score and the survival time of a patient. While it provides a measure of discrimination over the entire follow-up period of a study, the probability does not provide information on the longitudinal durability of a baseline risk score. It is possible that a baseline risk model is able to segregate short-term from long-term survivors but unable to maintain its discriminatory strength later in the follow-up period. As a consequence, this would motivate clinicians to re-evaluate the risk score longitudinally. This longitudinal re-evaluation may not, however, be feasible in many scenarios since a single baseline evaluation may be the only data collectible due to treatment or other clinical or ethical reasons. In these scenarios, an attenuation of the discriminatory power of the patient risk score over time would indicate decreased clinical utility and call into question whether this score should remain a prognostic tool at later time points. Working within the concordance probability paradigm, we propose a method to address this clinical scenario and evaluate the discriminatory power of a baseline derived risk score over time. The methodology is illustrated with two examples: a baseline risk score in colorectal cancer defined at the time of tumor resection, and for circulating tumor cells in metastatic prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrognosisProportional Hazards ModelsComputer SimulationHumansRisk AssessmentRisk FactorsTime

Stichwörter der Autor:innen

Concordance probabilityPrognostic modelingProportional hazards

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. devlins@mskcc.org.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Sean M Devlin

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Devlin, S. M., Gönen, M., & Heller, G. (2020). Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis, 26(4), 856-871. https://doi.org/10.1007/s10985-020-09503-3

Vancouver

Devlin SM, Gönen M, Heller G. Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis. 2020;26(4):856-871. doi:10.1007/s10985-020-09503-3

BibTeX
@article{Devlin2020,
  author = {Devlin, Sean M and Gönen, Mithat and Heller, Glenn},
  title = {Measuring the temporal prognostic utility of a baseline risk score},
  journal = {Lifetime Data Analysis},
  year = {2020},
  volume = {26},
  number = {4},
  pages = {856--871},
  doi = {10.1007/s10985-020-09503-3}
}
Kostenlos starten →